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Abstract
Alzheimer’s disease (AD) is a neurodegenerative condition which consists of stages of mental,
memory, and cognitive decline. As it continues to stand as the sixth leading cause of death in the
U.S., 44 million people worldwide are affected. The objective of this paper is to explore the risk
factors for AD in an attempt to examine potential causes for the incidence of AD. We examined
genetics, lifestyle, and pre-existing conditions as risk factors for AD. We found that there are
various alleles, such as APP, PSEN, ADAM, APOE, and TREM2, that play a role in the development
of AD. It was also determined that behavioral modifications such as following a Mediterranean
and ketogenic diet, engaging in regular intellectual activities, and participating in regular physical
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exercise can all reduce the risk of developing AD. The comorbidity of existing conditions such as
hypertension, diabetes mellitus, high cholesterol, and cardiovascular diseases all had an impact
on developing AD. There is evidence that genetics, lifestyle, and pre-existing conditions
significantly impact the incidence of AD; however, understanding how all these risk factors
interrelate with each other is a recommended topic for further study.
Keywords
Alzheimer’s Disease; neurodegenerative disorder; risk factors; genetics; lifestyle; pre-existing
conditions

1. Introduction
Alzheimer’s disease (AD) is a progressive neurological condition that causes deterioration in
memory, function, and behavior. It typically begins and remains in an asymptomatic phase for a long
period of time, followed by symptomatic pre-dementia phase and then can transition to the dementia
stage. It is estimated that 5.8 million Americans are affected by this disease in 2019. Health-care costs
for AD has been estimated to be about $172 billion per year [1].
This neurodegenerative disease is often characterized by mental decline, memory loss, confusion,
disorientation, and etc. along with possible behavioral, mood, and/or psychological changes.
Neuropathological hallmarks of AD are identified as extracellular depositions of amyloid-β (Aβ) peptide
in neuritic plaques and neurofibrillary tangles. Some changes such as microgliosis or loss of white
matter and neurons can also occur. However, mechanisms behind many of these processes are still
unknown. As Alzheimer’s remains as the sixth leading cause of death in the U.S., there is a need for
more research analyzing prevention, early detection, reversal, and treatments options [2].
This paper examines various risk factors playing a role in the incidence of Alzheimer’s disease. It is
important to investigate risk factors as it may open new doors in understanding Alzheimer’s disease
and allow for preventive and treatable measures to be taken. This paper evaluated the impact that
genetics, social and behavioral factors, and pre-existing conditions can have on the incidence of
Alzheimer’s disease.
2. Genetics
2.1 Deterministic Genes
2.1.1 APP, PSEN1, PSEN2
Early onset of Alzheimer’s can be caused by mutations to the transmembrane neuronal protein, βamyloid precursor protein (APP). Cleavage of APP by β-secretase and γ-secretase results in amyloid-β
peptide (Aβ). The amyloid cascade hypothesis states that mutations in APP or alterations in Aβ
homeostasis lead to an accumulation of Aβ and plaques, which can be enough to trigger pathological
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symptoms of Alzheimer’s. However, cleavage of APP by α-secretase shows neuroprotective effects as
it generates nonamyloidogenic fragments. Bioinformatic analysis show that rare variants of APP, such
as APP N660Y, can increase the risk of Alzheimer’s while APP A673T can decrease and APP E599K can
show no effect on the risk of developing Alzheimer’s [3].
Previous genome-wide association studies have found susceptibility loci, such as CLU, B1N1, and
CR1, that affect processes involving APP in non-Hispanic Whites [4].
CLU is also known as apolipoprotein J and mediates lipid transport. It is thought that CLU can affect
Aβ-aggregation and Aβ clearance via endocytosis by acting as an extracellular chaperone. B1N1 is part
of the Bin1/amphiphysin/RVS167 genes, which are involved in various cellular processes including
membrane trafficking and clathrin-mediated endocytosis. Since this family of genes are involved in
membrane transport and actin dynamics, B1N1 can affect processing, production or clearance of Aβ.
Additionally, CR1 is a cell receptor that participates in the complement system by binding to
complement factors C3b and C4b. It is found that Aβ oligomers bind to C3b so CR1 can possibly allow
clearance of Aβ. As part of the complement system, CR1 is also involved in neuroinflammation, which
is a characteristic of Alzheimer’s disease. However, CLU can also be an inhibitor in the process. This first
set of loci are involved in the metabolism, processing, or endocytosis of APP [5-7].
Additionally, ABCA7 is another identified susceptibility gene that is involved in the metabolism and
processing of APP. Part of the ABC family proteins, ABCA7 is a transmembrane ATP-binding cassette
transporter which controls the biogenesis of high-density lipoprotein and transport of important
proteins, such as amyloid precursor protein. In genome-wide association studies in African Americans,
ABCA7 is a major susceptibility locus and had a greater risk factor than compared to Caucasians. This
locus has a 70-80% increase in risk in African Americans while 10-20% increase in risk in Caucasians.
However, further studies in African Americans have to take place to confirm this as a target for
prevention, testing, and treatment for AD. In addition to genetic origins, studies have shown that
traumatic brain injury can vary the Aβ and tau pathologies in the brain. Changes such as elevated levels
of Aβ and overproduction of APP in the cerebrospinal fluid can occur [8, 9].
Mutations within presenilin (PSEN) 1 and PSEN2 increase γ-secretases leading to a buildup of
amyloid-β. Additionally, mutations in APP, Presenilin (PSEN) 1 and PSEN2 have also been linked to cause
early onset AD (EOAD) [10, 11].
APP, PSEN1 and PSEN2 genes are all inherited autosomal dominant, and mutations to these AD
genes have been found with high levels of Aβ aggregation and start of Alzheimer’s disease. As they are
involved in the EOAD, they can also be used as biomarkers [4].
Recent research points out that PSEN1 and PSEN2 mutations has been associated with late onset AD
(LOAD) as well but are unlikely to have a significant contribution towards the susceptibility of LOAD
[11].
2.2 APP-Modifying Genes
2.2.1 ADAM Family
The ADAM (A disintegrin and metalloprotease) family is responsible for controlling α-secretase
activity [12]. The enzyme α-secretase is responsible for cleaving APP in the middle of the Aβ domain
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[13]. There are three members of the ADAM family: ADAM9, ADAM10, ADAM17. Each member of this
family has a unique function [12]. ADAM9 is suggested to have an indirect role in modulating αsecretase cleavage. Unlike ADAM10, ADAM17 is not directly involved in the coordinated expression of
APP in the human brain. ADAM17 is required for phorbol myristate acetate (PMA) to increase αsecretase cleavage [14]. ADAM 10 is a type I membrane protein and is most notably known for its
combined ability to regulate and constitute α-secretase activity along with being responsible for
coordinating mRNA expression of APP in human neurons [12].
Patients with sporadic Alzheimer’s patients have been reported to have decreased levels of ADAM10
and sAPPα levels. Moreover, it has been observed that mice with excess ADAM10 expression have
elevated sAPPα levels and reduced Aβ formation [12]. The ADAM10 promoter region contains a
transcriptional binding site that is responsive to retinoic acid. Retinoic acid along with other vitamin A
derivatives, in theory, should increase the expression of ADAM10, which will in turn elevate APP αsecretase cleavage and reduce Aβ plaque accumulations. This points at retinoic acid as a possible drug
that could be tested in the future to determine if it would have an effect on AD [14].
The Q170H and R181G mutations in ADAM10 sharply decreases the α-secretase activity of ADAM10
further leading to increases in Aβ plaques. Q170H and R181G mutations have been partially penetrant
in familial LOAD. The mutations affecting late onset instead of early onset draws attention to the small
effect Aβ plaque accumulation plays in LOAD compared to EOAD mutations in APP, PSEN1, and PSEN2
[12].
2.3 Risk Genes
2.3.1 APOE
The APOE allele, which produces the apolipoprotein E, have been identified as a major genetic risk
factor for AD. APOE, a lipid transport protein, is present in plasma and in the brain. It is secreted by glia,
and as a result it is also present in the CSF. Although the mechanism is not clear, there is evidence that
shows APOE can affect neural plasticity and structure which can further the progression of AD. It is
hypothesized that APOE can interact with and influence the clearance and deposition of amyloid-β
peptide. Studies in vivo have shown that APOE can colocalize with Aβ in the brains of Alzheimer’s
disease. While studies in vitro have shown that through an isoform specific manner, APOE binds to Aβ
and can affect Aβ fibril formation. However, other factors such as the lipidation state of APOE and the
presence of binding proteins can affect these results, thus causing difficulty in understanding this
process [15].
For more than ten years, it had been thought the APOEɛ4 allele on chromosome 19q13 causes
susceptibility to AD in non-Hispanics Whites. Three alleles ɛ2, ɛ3, and ɛ4 produces three isoforms of
APOE. Receiving one copy of the APOEɛ4 allele causes a two or three-fold increased risk, while receiving
two copies of the APOEɛ4 allele causes a five or more-fold increase in risk. In addition, each copy lowers
the age at which disease starts by six to seven years [2]. In general, there is a correlation between
increasing the gene dose of APOEɛ4 allele and the increased number of Aβ in AD patients. For instance,
studies using transgenic mice that express mouse APOE4 or human APOE3 or APOE4 were used to
understand the APOE/Aβ interactions in the pathogenesis of Alzheimer’s disease. To understand the
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role of APOE/Aβ in the pathogenesis of Alzheimer’s disease, expression of APOE4 gene in mice and
APOE3 and APOE4 genes in human were studied. It was found that human APOE isoforms had
suppressed deposition of Aβ for 6 or more months longer, and there were reduced levels of total Aβ in
the hippocampus compared to the mice of mouse APOE. However, following the inhibition of
deposition in human APOE expressing mice, accumulation of Aβ resulted in Aβ fibrils and plaques. The
study also found that by 15 months of age, 89% of the APOE4 mice had deposits of Aβ in the
hippocampus compared to only 39% of APOE3 mice. As a result, APOE4 poses a greater Aβ burden in
terms of Aβ fibrils and neuritic plaque compared to APOE3 [16].
Although APOEɛ4 can correlate to low levels of cognitive performance in terms of memory, the
presence of the allele is not required nor enough to cause the development of AD. The inconsistent
association between the ɛ4 and late onset AD was seen in other ethnic groups, those that are not nonHispanics Whites. On the other hand, research identified APOE as a susceptibility gene in African
Americans, while this finding was inconsistent across previous studies [4].
Additional factors, such as traumatic head injury, when coupled with the APOEɛ4 allele can have
synergistic effects on the incidence of AD. For instance, when there was a history of head injury with
APOE4 in the elderly person, the risk of AD increased by 10-fold compared to the two-fold increase with
APOE4 alone or to the absence of risk with head injury alone [17].
2.3.2 TREM2
The TREM2 receptor on microglia is utilized for phagocytosis and inflammation repression. A rare
missense mutation in the TREM2 gene is associated with an increase in the risk of late onset Alzheimer's
disease. The variant R47H in specific is reported to increase the risk of late onset of Alzheimer’s disease
by two-fold. Not only does this variant increase the risk for Alzheimer’s disease, it is also linked to
Parkinson’s disease, dementia, and sclerosis. After the TREM2 receptor is expressed on the cell
membrane, it is cleaved by gamma-secretase. TREM2 is suggested to play an important role in
neurodegeneration and clearing proteins through itself phagocytic pathway [18].
3. Behavioral/Social
3.1 Educational Attainment & Intellectual Activity
The level of educational attainment and the amount of intellectual activity has been associated with
the development of Alzheimer’s disease. There have been many studies concluding that patients with
Alzheimer’s disease typically have lower amounts of intellectual activities throughout their lives.
Results from one study, in particular, showed that low levels of educational attainment, as well as low
participation in intellectual activities in midlife, is a risk factor for Alzheimer’s disease. The study also
reported people with less physical activity combined with a lack of intellectual activities had an increase
in the risk of developing Alzheimer’s disease by about 250% [19].
Another study concluded similar results and also reported strong evidence of a causal, bidirectional
relationship between intelligence and education attainment. It is theorized that the learning complex
can increase synaptic connections in the gray matter of the brain and causes structural changes in the
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white matter which may contribute to increased intelligence. The findings of the study revealed
increasing levels of educational attainment could reduce the incidence of Alzheimer’s disease [20].
Given that many studies have concluded that educational attainment can play a role in reducing the
risk of developing Alzheimer’s disease, it is important for the public to be aware of this information.
Countries like the UK have implemented changes in schooling legislation to mandate students to stay
in school until the age of 18. Possibly mandating higher education beyond the age of 18 could aid in
reducing the incidence of Alzheimer’s disease. However, if this is not a feasible option for everyone
then governmental recommendations should suggest that people partake in regular cognitive training
throughout life [20].
3.2 Diet
There has been some research showing that poor diet, such as high saturated fat and low vegetable
intake, can increase the risk of Alzheimer’s. There are a small number of studies on individual dietary
components and data. However, there is increasing evidence showing that specific dietary practices,
such as Mediterranean diet, can lower the risk of AD, while independent of physical activity and other
comorbidities [21].
A Mediterranean diet consists of fish and plant foods, wine and olive oil as a source of
monounsaturated fats, and low in red meat and poultry intake. The high amounts of antioxidants and
polyunsaturated fatty acids in fruits, vegetables, and fish can reduce the incidence of AD as it has been
found that reactive oxygen species is associated with neuronal damage in AD [22, 23].
As depositions of Aβ increase, the levels of iron and copper reduce, resulting in oxidative and
neuronal damage [24]. The intake of antioxidants can possibly decrease the risk of AD by lowering the
risk of cerebrovascular disease [25].
While polyunsaturated fatty acids reduce oxidative stress and help with inflammatory processes and
neuronal and vascular functions, some studies had inconclusive results regarding its impact and
association with cognitive performance. On the other hand, in vitro studies have shown that Aβ-lipid
peroxidation can be reduced by vitamin E, and carotenes and vitamin C can lower levels of lipid
peroxidation and formation of nitrosamines. However, there are some inconclusive results about the
impact of vitamin E and C [26-29].
As studies have tested the effects of cholesterol and saturated fats in relation to the development
of AD, Van der Auwera et al. have shown the effects of a ketogenic diet (high saturated fats and low
carbohydrates intake) on a transgenic mouse model. Mice fed the ketogenic diet had increased levels
of ketone bodies, such as β-hydroxybutyrate, but lost body weight. Previous studies assessed the
individual effect of high saturated fats which can increase the risk of AD. However, this study showed
that a combined diet of lipid rich and low carbohydrates can decrease the total brain Aβ levels [30].
The ketogenic diet has a very high-fat, low-carbohydrate content. It increases mitochondrial function
and cellular metabolism, which may result in enhanced cognitive functioning in elderly patients with
Alzheimer’s Disease. The best results of KD treatment are expected in early presymptomatic stages of
AD. This type of diet may cause hypoglycemia and dehydration [31].
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3.3 Physical Activity
Some studies have shown that increases in physical activity have been linked to a reduction in the
risk of developing Alzheimer’s disease. Regular physical activity has been shown to decrease the risk of
getting Alzheimer’s disease by up to 31%. Unlike other risk factors, this decrease is highly significant.
This allows for additional interventions to reduce the risk of developing Alzheimer’s disease.
Additionally, this points to a modifiable lifestyle habit that has the ability to reduce the risk of AD. While
the exact method cause of Alzheimer’s disease is yet to be known, regular exercise allows for people
genetically predisposed to AD to have a way to reduce their chances of developing AD [32-35].
A longitudinal study sought out to determine if leisure physical activity throughout midlife would
have an effect on the risk of developing Alzheimer’s disease and dementia. Patients were determined
through questionnaires to evaluate their leisure-time physical time. After this information was
recorded, participants were re-evaluated 21 years later. After multiple logistic regression, it was found
that participants that incorporated leisure activity at least twice a week during their midlife had a
reduced risk of dementia and Alzheimer’s disease. The odds of getting Alzheimer’s disease were 60%
lower for those who exercised twice a week. The effects that physical activity had against dementia and
Alzheimer’s disease were more significant with APOEɛ4 carriers, nevertheless, the study still showed
significant results for non-carriers. The criteria for assessing leisure physical were if the participant
participates in at least 20-30 minutes of physical activity that causes breathlessness and sweating. This
could include anything from dancing to speed walking. The protective role that physical activity plays is
rather significant and should be evaluated further as a possible way to prevent Alzheimer’s disease.
Simply adopting a more physically active lifestyle can go a long way in reducing the risk of Alzheimer’s
Disease [35].
4. Existing Conditions
4.1 Hypertension
Raised systolic blood pressure and hypercholesterolaemia in midlife can contribute to the onset of
Alzheimer’s disease. A longitudinal, population-based study showed that of 1449 people aging from 6579, 48 fulfilled the criteria for possible Alzheimer’s. These patients were significantly older, had less
formal education, and had a higher body mass index, serum cholesterol, and systolic blood pressure.
However, no changes in diastolic blood pressure were observed. Participants with both high systolic
pressure and serum cholesterol posed a higher risk of Alzheimer’s and/or of myocardial infarction and
cerebrovascular symptoms. Other studies have shown the risk can be related to raised diastolic blood
pressure which can be due to the settings or populations of the studies. A study by Skoog et al. reported
an increase in systolic and diastolic blood pressure 10-15 years prior to the onset of Alzheimer’s disease
[36].
Individuals with hypertension commonly exhibit an increase in senile plaques and neurofibrillary
tangles [37].
Participants with Alzheimer’s were likely to have received antihypertensive drugs in their midlife but
have shown high systolic blood pressure later on. This signifies how high diastolic pressure is targeted
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for treatment, but even after receiving the treatment, they may not be able to achieve the desired
blood pressure. Hypertension can also impact the blood brain barrier and cause protein extravasation
into the brain tissue. This can result in damage to and apoptosis of cells, reduction of neuronal function,
or beta-amyloid plaque accumulation which causes cognitive impairment [38].
Interestingly, with increasing age, the risk of elevated blood pressure for Alzheimer’s disease
decreases and can even provide a protective role. During the onset of Alzheimer’s, weight loss, vessel
stiffening, or changes in blood flow can consequently reduce blood pressure.
4.2 Cholesterol
Biochemical and epidemiological studies have shown a relation of Aβ-amyloid peptide, amyloid
precursor protein, and cholesterol to Alzheimer’s disease. Hypertension and hypercholesterolemia can
cause atherosclerosis; impaired blood flow can contribute to the neurodegeneration seen in
Alzheimer’s disease. The combination of these two risk factors increases the risk for Alzheimer’s [38].
Genetic linkage and association studies have reported certain genes involved in cholesterol
transport or metabolism increase the susceptibility to Alzheimer’s. These genes include ATP-binding
cassette subfamily A member 7, apolipoprotein E, apolipoprotein J, and sortilin-related receptor [2].
Other studies have shown that cholesterol can alter beta-amyloid production by interfering with the
process of beta-secretase and gamma-secretase enzymes acting upon beta-amyloid precursor.
Additionally, cellular cholesterol also inhibits the colocalization of beta-secretase 1 and beta-amyloid
precursor, resulting in a rise of plasmin, a beta-amyloid-degrading enzyme. Functional cell biology show
that increased membrane cholesterol can be protective of the membrane due to amyloid cytotoxicity
[2, 39].
In a study with 444 Finnish men aging from 70 to 89 years, high serum cholesterol levels of ≥6.5
mmol/l was associated with Alzheimer’s disease. Factors such as apolipoprotein E gene and age were
controlled. Of those who developed AD, a decrease in serum cholesterol levels before the symptoms
of AD appeared was observed, supporting cholesterol’s protective role. In the Rotterdam study, it was
found that there was no relation between serum cholesterol and dementia. However, a high dietary
intake of saturated fat, total fat, and cholesterol increased the risk of both Alzheimer’s and dementia.
Intake of fish with n-3 polyunsaturated fatty acids decreased the risk of both dementia and Alzheimer’s
disease [40].
A study done by Sparks et al. showed that brains of rabbits with a high cholesterol diet had amyloid
accumulations [41]. However, there are few studies to show the relation of cholesterol to Alzheimer’s.
A case control study based on a small hospital population showed Alzheimer’s patients had higher mean
cholesterol levels compared to controls. It was thought the apolipoprotein E gene impacted the
cholesterol levels in these patients [42-44].
Based on a recent metanalysis study, the effect of LDL cholesterol in development of AD is important
and higher level of LDL cholesterol in midlife is considered an independent risk factor for AD later in
life. However, the effects of HDL cholesterol, total cholesterol and triglyceride levels were not
statistically significant when compared with healthy control group [45].
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The level of HDL cholesterol is controversial. Some studies indicate that lower level of HDL-C does
not corelated with development of Alzheimer’s disease [46-49]. However, some other studies indicate
higher chance of developing AD if the patient suffers from lower level of HDL-C [50, 51].
4.3 Diabetes Mellitus (DM)
Diabetic patients have higher likelihood of developing dementia later in life [52, 53]. Risk factors for
DM and AD somewhat tend to have similarities. Both conditions have inflammation, oxidative stress,
and mitochondrial dysfunction. Brain insulin resistance and amyloidogenesis are crucial for
hyperglycemia-induced deficiency of mental function [54].
It is suggested that hyperglycemia influences the neuronal damage and death which could
eventually lead to a series of pathological changes. These pathological changes could induce amyloid
plaque deposits leading to the development of Alzheimer’s disease. Advanced glycation end products
increase as people age; however, in diabetic patients, the rate of development of advanced glycation
end products is accelerated. However, there is still much debate whether it plays a role in the
development of Hirano bodies, neurofibrillary tangles, and beta-amyloid plaques which are indicative
of Alzheimer’s disease [55].
4.4 Cardiovascular Disease (Homocysteine)
It has been determined that elevated homocysteine levels are associated with atherosclerosis and
an increase in the incidence of a stroke. Thus, the magnitude of increase in plasma homocysteine levels
is correlated with an increased risk of death due to cardiovascular problems and the development of
Alzheimer’s disease. However, it has been established that an increase in homocysteine levels is also
linked to Alzheimer’s disease. An increase in plasma homocysteine levels from baseline by 5 µmol per
liter increased the risk for the development of Alzheimer’s disease by 40% [56].
In isolation of the resultant vascular consequences, a study evaluated cases where abnormally high
levels of plasma homocysteine levels resulted in Alzheimer's disease without the presence of any
vascular symptoms. Additionally, it was determined from a rat study that homocysteine promotes beta
amyloid aggregation, in turn, inducing severe apoptosis in hippocampal cells [56]
Additional research points out that homocysteine and folate levels are inversely proportional to each
other [57]. Hyperhomocysteinemia has been established to be a strong independent risk factor for
Alzheimer’s disease [56]. Therefore, efforts should be placed on detecting homocysteine levels before
Alzheimer’s disease develops in patients. It has been suggested that government-mandated folate and
homocysteine be in place to reduce the incidence of AD. Efforts should be placed on early detection of
AD and should be furthered researched if decreasing homocysteine and increasing folate could prevent
Alzheimer’s disease [58].
5. Conclusion
Since Alzheimer’s disease starts to progress years before symptoms appear, early detection and
reversal is difficult. With AD being one of the three leading causes of death in the older population, AD
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remains to be a complex series of changes in the brain, which is not fully understood by researchers as
it is a multifactorial disease influenced by genetics, environment, and lifestyle. With genetics, there are
multiple alleles and variants that play a role in the development of AD, and some AD-prone alleles can
combine to produce an even more pronounced risk of AD. It is important to note that these identified
alleles can have varied effects on specific populations depending on their demographics. Recent
research has explored the impact that social and behavior modifications can have on the incidence of
AD. Diets high in saturated fats with low vegetable intake can increase the risk of AD while following a
Mediterranean diet has been associated with a lower risk of AD. Also, participating in regular physical
exercise and engaging in intellectual activities has been seen to reduce the chances of developing AD.
The comorbidity of some existing conditions and Alzheimer’s disease can exacerbate the effects of AD
on patients. However, some pre-existing conditions can actually play a protective role as the patient
ages. Awareness about the many different actions people should take to help reduce their risk for AD
should be spread as a public health initiative. AD is a detrimental disease that has a significant impact
on the quality of life of patients, thus further research should not only include exploring how AD is
caused, but also potential treatment options for AD should be investigated.
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